Model-informed Drug Development of Envafolimab, a Subcutaneously Injectable PD-L1 Antibody, in Patients with Advanced Solid Tumors.
The Oncologist（2024）
Key words
envafolimab,PD-L1 antibody,subcutaneous injection,population pharmacokinetics,exposure-response analysis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined